Human HER2 / ErbB2 Protein (Fc Tag)
CD340,HER-2,HER-2/neu,HER2,MLN 19,MLN19,NEU,NGL,TKR1
- 100ug (NPP1530) Please inquiry
| Catalog Number | P10004-H02H |
|---|---|
| Organism Species | Human |
| Host | Human Cells |
| Synonyms | CD340,HER-2,HER-2/neu,HER2,MLN 19,MLN19,NEU,NGL,TKR1 |
| Molecular Weight | The recombinant human ErbB2/Fc chimera is a disulfide-linked homodimeric protein generated by proteolytic removal of the signal peptide. The monomer comprises 868 amino acids and has a calculated molecular mass of 96.1 kDa. As a result of glycosylation, the monomer migrates as an approximately 130-140 kDa protein in SDS-PAGE under reducing conditions. |
| predicted N | Thr 23 |
| SDS-PAGE |  |
| Purity | > 90 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the extracellular domain (Met 1-Thr 652) of human ErbB2 (NP_004439.2) was fused with the Fc region of human IgG1 at the C-terminus. |
| Bio-activity | Measured by its binding ability in a functional ELISA . Immobilized human ErbB2 at 2.5 μg/ml can bind Herceptin with a linear range of 3.2-80 ng/ml . |
| Research Area | Cardiovascular |Angiogenesis |Growth Factor & Receptor |Receptor Tyrosine Kinase (RTK) |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on. |
| Reference |